{"id":169172,"date":"2025-07-17T06:14:32","date_gmt":"2025-07-17T10:14:32","guid":{"rendered":"https:\/\/44.250.171.167\/?p=169172"},"modified":"2025-07-17T06:14:32","modified_gmt":"2025-07-17T10:14:32","slug":"global-health-ltd-q4fy25-20-fall-in-profits-2","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/global-health-ltd-q4fy25-20-fall-in-profits-2\/","title":{"rendered":"Global Health Ltd Q4FY25; 20% fall in Profits"},"content":{"rendered":"<p>Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.<\/p>\n<p>Financial Results:<\/p>\n<p>Global Health Ltd reported Revenues for Q4FY25 of \u20b9931.00 Crores up from \u20b9809.00 Crore year on year, a rise of 15.08%.<\/p>\n<p>Total Expenses for Q4FY25 of \u20b9771.00 Crores up from \u20b9692.00 Crores year on year, a rise of 11.42%.<\/p>\n<p>Consolidated Net Profit of \u20b9101.00 Crores down 20.47% from \u20b9127.00 Crores in the same quarter of the previous year.<\/p>\n<p>The Earnings per Share is \u20b93.78, down 20.25% from \u20b94.74 in the same quarter of the previous year.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-169173\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-6.png\" alt=\"\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-6.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-6-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-6-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-6-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-6-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology. Financial Results: Global Health Ltd reported Revenues for Q4FY25 of [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":169173,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[12045],"class_list":["post-169172","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-cardiology"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-6.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":169160,"url":"https:\/\/alphastreet.com\/india\/global-health-ltd-q4fy25-20-fall-in-profits\/","url_meta":{"origin":169172,"position":0},"title":"Global Health Ltd Q4FY25; 20% fall in Profits","author":"Divyansh_Kasana","date":"July 16, 2025","format":false,"excerpt":"Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology. Financial Results: Global Health Ltd\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/J-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/J-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/J-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/J-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/J-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/J-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168730,"url":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-india-ltd-q4fy25-3-rise-in-revenue\/","url_meta":{"origin":169172,"position":1},"title":"Astrazeneca Pharma India Ltd Q4FY25; 3% rise in Revenue","author":"Divyansh_Kasana","date":"June 10, 2025","format":false,"excerpt":"AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. Financial Results: Astrazeneca Pharma India Ltd reported Revenues for Q4FY25 of \u20b91,000.00 Crores up from \u20b9974.00 Crore year on year, a rise of 2.67%. Total Expenses for Q4FY25 of \u20b9914.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169024,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q4fy25-23-rise-in-profits-2\/","url_meta":{"origin":169172,"position":2},"title":"Divis Laboratories Ltd Q4FY25; 23% rise in Profits","author":"Divyansh_Kasana","date":"July 7, 2025","format":false,"excerpt":"Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients Financial Results: Divis Laboratories Ltd reported Revenues for Q4FY25 of \u20b92,585.00 Crores up from \u20b92,303.00 Crore year on year, a rise of 12.24%. Total Expenses for Q4FY25 of \u20b91,807.00 Crores up from \u20b91,669.00 Crores year on\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169071,"url":"https:\/\/alphastreet.com\/india\/emcure-pharmaceuticals-ltd-q4fy25-63-rise-in-profits\/","url_meta":{"origin":169172,"position":3},"title":"Emcure Pharmaceuticals Ltd Q4FY25; 63% rise in Profits","author":"Divyansh_Kasana","date":"July 9, 2025","format":false,"excerpt":"Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally Financial Results: Emcure Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b92,116.00 Crores up from \u20b91,771.00 Crore year on year, a rise of 19.48%. Total Expenses for Q4FY25 of \u20b91,850.00 Crores up from \u20b91,616.00 Crores year on year, a\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169080,"url":"https:\/\/alphastreet.com\/india\/eris-lifesciences-ltd-q4fy25-28-rise-in-profits\/","url_meta":{"origin":169172,"position":4},"title":"ERIS Lifesciences Ltd Q4FY25; 28% rise in Profits","author":"Divyansh_Kasana","date":"July 10, 2025","format":false,"excerpt":"ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. Financial Results: ERIS Lifesciences Ltd reported Revenues for Q4FY25 of \u20b9705.00 Crores up from \u20b9551.00 Crore year on year, a rise of 27.95%. Total Expenses for Q4FY25 of \u20b9584.00 Crores up from \u20b9489.00 Crores year\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169156,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q4fy25-6-rise-in-revenue\/","url_meta":{"origin":169172,"position":5},"title":"Glenmark Pharmaceuticals Ltd Q4FY25; 6% rise in Revenue","author":"Divyansh_Kasana","date":"July 16, 2025","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b93,256.20 Crores up from \u20b93,062.96 Crore year on year, a rise of 6.31%. Total Expenses for Q4FY25\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=169172"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169172\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/169173"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=169172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=169172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=169172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}